WILMINGTON, Mass., May 19, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB:IMSC), a high technology supplier of
systems and sensors for homeland security and defense markets,
today announced it will exhibit its QS-B220 explosives trace
detector at booth # 256 at the 86th Annual American
Association of Airport Executives (AAAE) Conference &
Exhibition on May 19th
through 21st, 2014 in San
Antonio, Texas.
Implant Sciences became a member of the AAAE earlier this year.
AAAE's Carter Morris, host of "One
on One," recently interviewed Dr. Bill
McGann, Chief Operating Officer of the Implant Sciences
Corporation. See the interview at:
https://www.youtube.com/watch?v=K2Rg2g_WaMs
"AAAE is an organization that expedites the communication of the
numerous benefits our QS-B220 provides to both airports and
travelers. As the QS-B220 continues to progress through the final
stage of TSA Checkpoint Qualification testing, this conference will
facilitate building relationships to help improve security across
the Americas," stated Glenn D.
Bolduc, President and CEO of Implant Sciences
Corporation.
The 86th Annual AAAE Conference and Exposition is the
airport industry's premier gathering of the world's most
influential airport executives. Decision makers from more than 250
airports are expected to attend the conference. Founded in 1928,
AAAE is the world's largest professional organization for airport
executives, representing thousands of airport management personnel
at public-use commercial and general aviation airports. The
organization's members represent approximately 850 airports and
hundreds of companies and organizations that support airports.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives. With significantly lower
maintenance requirements than competing systems, the QS-B220 can be
deployed for a much lower total cost of ownership than other
approved products. Featuring a radioactive material-free design,
push-button maintenance and diagnostics, and a patented inCal™
internal automatic calibration system, the QS-B220 brings new
levels of performance and convenience to desktop trace detection
users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's QS-B220 has received approvals and certifications
from several international regulatory agencies including the TSA in
the U.S., STAC in France, the
German Ministry of the Interior, and the Ministry of Public Safety
in China. It also received a GSN
2013 Homeland Security Award for "Best Explosives Detection
Solution". All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
our explosives detection products and technologies (including any
new products we may develop) may not be accepted by the
Transportation Security Administration or by other U.S. or foreign
government and law enforcement agencies or commercial consumers of
security products; economic, political and other risks associated
with international sales and operations could adversely affect our
sales; our business is subject to intense competition and rapid
technological change, and our success will depend on our ability to
develop and introduce new products; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including our most recent Forms 10-K, 10-Q and
8-K. Such statements are based on management's current expectations
and assumptions which could differ materially from the
forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation